A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients

Inclusion Criteria Concurrent Medication: Recommended: * PCP prophylaxis. Allowed: * Antiretroviral therapy during induction and pharmacokinetic part of study, provided patient remains on the same antiretroviral therapy for the duration of the study. * Chemotherapy for Kaposi's sarcoma, provided patient is hematologically stable for at least 30 days prior to study entry. * Recombinant human erythropoietin. * GM-CSF and G-CSF. * Other medications necessary for patient's welfare, at the physician's discretion. Patients must have: * HIV infection. * Biopsy-proven cytomegalovirus (CMV) colitis. * Life expectancy of at least 3 months. * No active AIDS-defining opportunistic infection requiring therapy that is known to cause nephrotoxicity or myelosuppression. NOTE: * Kaposi's sarcoma is permitted if patients are hematologically stable for at least 30 days prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Other etiologies for diarrhea identified at study entry. PER AMENDMENT 3/14/95: * For subjects who have diarrhea - no other etiologies for diarrhea identified within 6 weeks of enrollment. * Known hypersensitivity to study drugs. * CMV retinitis. Concurrent Medication: Excluded: * Acyclovir or probenecid (PER AMENDMENT 3/14/95). * Immunomodulators. * Biologic response modifiers (other than GM-CSF or G-CSF). * Investigational agents, with the exception of treatment IND drugs. * Antaci…